**We claim:**

1. Use of a 5-$HT_4$ receptor agonist, in the manufacture of a medicament for the treatment of dementia due to menopause, cognitive deficits associated with schizophrenia, depression, chemotherapy-induced cognitive impairment, or behavioral and psychological symptoms of dementia, wherein the 5-$HT_4$ receptor agonist is a compound, Isopropyl-3-{5-[1-(3-methoxypropyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole or a pharmaceutically acceptable salt thereof; and the behavioral and psychological symptoms of dementia are selected from agitation, aggression or depression.

2. Use of a 5-$HT_4$ receptor agonist as claimed in claim 1, wherein the pharmaceutically acceptable salt of Isopropyl-3-{5-[1-(3-methoxypropyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole is selected from mesylate, hydrochloride, oxalate, succinate, fumarate or tartrate salt.

3. Use as claimed in claim 1 or claim 2, wherein the pharmaceutically acceptable salt of Isopropyl-3-{5-[1-(3-methoxypropyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole is Isopropyl-3-{5-[1-(3-methoxypropyl) piperidin-4-yl]-[1,3,4]oxadiazol-2-yl}-1H-indazole oxalate.

4. Use of a 5-$HT_4$ receptor agonist as claimed in any one of claims 1 to 3, in the manufacture of a medicament for the treatment of dementia due to menopause.

5. Use of a 5-$HT_4$ receptor agonist as claimed in any one of claims 1 to 3, in the manufacture of a medicament for the treatment of cognitive deficits associated with schizophrenia.

6. Use of a 5-$HT_4$ receptor agonist as claimed in any one of claims 1 to 3, in the manufacture of a medicament for the treatment of depression.

7. Use of a 5-$HT_4$ receptor agonist as claimed in any one of claims 1 to 3, in combination with a selective serotonin reuptake inhibitor in the manufacture of a medicament for the treatment of depression, wherein the selective serotonin reuptake inhibitor is paroxetine.

8. Use of a 5-$HT_4$ receptor agonist as claimed in any one of claims 1 to 3, in the manufacture of a medicament for the treatment of chemotherapy-induced cognitive impairment.

9. Use of a 5-$HT_4$ receptor agonist as claimed in any one of claims 1 to 3, in the manufacture of a medicament for treating behavioral and psychological symptoms of dementia, wherein the behavioral and psychological symptoms of dementia are selected from agitation, aggression or depression.

10. The use of a 5-$HT_4$ receptor agonist as claimed in claim 9, wherein the behavioral and psychological symptom of dementia is selected from aggression in Alzheimer's disease, agitation in Alzheimer's disease, depression in Alzheimer's disease, aggression in Parkinson's disease, agitation in Parkinson's disease or depression in Parkinson's disease.

11. Use of a pharmaceutical composition comprising a 5-$HT_4$ receptor agonist as claimed in any one of claims 1 to 3 and pharmaceutically acceptable excipients in the manufacture of a medicament for the treatment of dementia due to menopause, cognitive deficits in schizophrenia, depression, chemotherapy-induced cognitive impairment, or behavioral and psychological symptoms of dementia, wherein the behavioral and psychological symptoms of dementia are selected from agitation, aggression or depression.

12. The use of pharmaceutical composition as claimed in claim 11, wherein the medicament is to be administered to the patient by oral, nasal, local, or parenteral routes.